Table 1. BMI-1 protein expression in tumours related to clinicopathologic variables and biomarkers in a population-based study of endometrial carcinomasa.
BMI-1 expressionb
|
|||
---|---|---|---|
Low | High | ||
Variable | n (%) | n (%) | P-value |
FIGO stage | 0.39 | ||
I/II | 118 (56) | 94 (44) | |
III/IV | 25 (49) | 26 (51) | |
Histologic subtype | 0.43 | ||
Endometrioid | 127 (53) | 111 (47) | |
Non-endometrioid | 16 (62) | 10 (38) | |
Histologic grade (FIGO) | 0.38 | ||
Grades 1–2 | 112 (53) | 100 (47) | |
Grade 3 | 31 (60) | 21 (40) | |
Vascular invasion | <0.0001 | ||
Not present | 74 (44) | 93 (56) | |
Presentc | 69 (71) | 28 (29) | |
Myometrial infiltration | 0.004 | ||
<50% | 56 (49) | 58 (51) | |
⩾50% | 50 (70) | 21 (30) | |
ER | 0.001 | ||
Low expression | 44 (77) | 13 (23) | |
High expression | 85 (51) | 82 (49) | |
PR | 0.03 | ||
Low expression | 46 (69) | 21 (31) | |
High expression | 84 (53) | 74 (47) |
ER=estrogen receptor; FIGO=Federation of Gynecology and Obstetrics; PR=progesterone receptor.
Two hundred and sixty-four cases with evaluable staining for BMI-1 (Upstate), missing data for FIGO stage in 1 case, depth of myometrial infiltration in 79 cases, for ER in 40 cases, and for PR in 39 cases.
Median used as cut-off value.
Vascular invasion of tumour cells detected in ⩾2 vessels.